期刊文献+

血管扩张剂治疗慢性心力衰竭的临床治疗 被引量:4

The Clinical Treatment of Chronic Heart Failure With Vasodilator
下载PDF
导出
摘要 目的探讨血管扩张剂治疗慢性心力衰竭常用药物与效果。方法选取2013年1月-2014年6月收治的慢性心力衰竭患者30例使用血管扩张剂治疗方法资料进行分析。结果 30例慢性心力衰竭患者治疗后病情均有不同程度的缓解,治愈11例,好转18例,无效1例,总有效率96.6%。结论心脏作功更直接地取决于外周循环的状态,对心肌衰竭患者应用血管扩张剂就是为了直接来影响决定患者症状的两个参数LVFP及心排血量。 Objective The commonly-used vasodilator medicine and its efficacy in treatment of chronic heart failure are to be investigated. Methods Analyze the vasodilator medicine treatment data selected from 30 patients of chronic heart failure who are treated in hospital from January 2013 to June 2014. Results Al of 30 patients’ symptoms have been relieved to some extent after treatment;11 patients are cured and 18 patients have an improvement in their health state,and 1 case is ineffective,the efficiency rate is up to 96.6% in total. Conclusion Cardiac function is directly determined by its peripheral circulation condition;therefore,the aim of application of vasodilator in treatment of patients with chronic heart failure is to directly influence two parameters LVFP and cardiac output,which would affect patients’ symptoms.
作者 周正弘
出处 《中国卫生标准管理》 2015年第3期244-245,共2页 China Health Standard Management
关键词 慢性心力衰竭 血管扩张剂 药物治疗 Chronic heart failure, Vasodilator, Medical treatment
  • 相关文献

参考文献1

二级参考文献29

  • 1The PEACE Investigators.Angiotensin-converting enzyme inhibition in stable coronary artery disease[J].N Engl J Med,2004,351:2058-2068.
  • 2Pfeffer MA,Braunwald E,Moye LA,et al.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.Results of the survival and ventricular enlargement trial[J].N Engl J Med,1992,327:669-677.
  • 3Dickstein K,Kjekshus J.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomized trial[J].Lancet,2002,360:752-760.
  • 4Dbrgie HJ.Effect of carvedilol on outcome after myocardial infartion in patients with left ventricular dysfunction:the CAPRICORN randomized trial[J].Lancet,2001,357:1385-1390.
  • 5Moss AJ,Zebraba W,Hall WJ,et al.Multicenter Automatic Defibrillator Implantation TrialⅡ Investigators:Prophylactic implantation of a defibrillation in patients with myocardial infarction and reduced ejection fraction[J].N Engl J Med,2002,346:877-883.
  • 6Gregoratos G,Abram J,Epstein AE,et al.ACC/AHA/NASPE 2002 guideline for implantation of cardiac pacemakers and antiarrhythmia device[J].J Cardiovasc Electrophysiol,2002,13:1183-1199.
  • 7Cohn JN,Tognoni G.A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure[J].N Engl J Med,2001,345:1667-1675.
  • 8Pfeffer MA,Swedberg K,Granger CB,et al.CHARM Investigators and Committee:Effects of candesartan on mortality and morbidity in patients with heart failure:the CHARM-Overall programme[J].Lancet,2003,362:759-766.
  • 9Ditt B,Remme W,Zannad F,et al.Eplerenoen,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction[J].N Engl J Med,2003,348:1309-1321.
  • 10Taylor AL,Ziesche S,Yancy C,et al.Combination of isosorbide dinitrate and hydralazine in blacks with heart failure[J].N Engl J Med,2004,351:2049-2057.

共引文献12

同被引文献40

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部